Verbatim response from Claude
This is a fast-changing area, so I want to be straightforward with you:
What's Happening
The FDA declared the semaglutide shortage over, which means compounding pharmacies are supposed to stop making copies of branded GLP-1s like Ozempic/Wegovy. Tirzepatide (Mounjaro/Zepbound) followed similarly.
The Current Landscape (as of early 2025)
Some telehealth platforms were still navigating legal challenges or winding down:
- Hims & Hers - fought the FDA ruling but has been transitioning away
- Ro - similar situation, adjusting offerings
- Sesame - connecting patients with providers but formularies changing
- Henry - was offering compounded options, status shifting
My Honest Advice
I'd caution you here rather than just recommend:
- Availability changes week to week due to ongoing litigation
- Some providers are still offering compounded versions in legal gray areas
- Quality control with compounding pharmacies varies significantly
- What's available today may not be tomorrow
Better Steps
- Check each platform's current website directly - information changes rapidly
- Ask specifically what pharmacy compounds their product
- Consider branded options through GoodRx or manufacturer savings programs
- Consult your doctor about the safest current path
Would you like help thinking through the branded medication access options instead?